The episodes are triggered by the release of norepinephrine in the cerebellum, which is the most important brain region for coordinating movement. Currently, there is no cure for ataxia. Therefore, ...
Andrew G. Lee, MD, was joined by Drew Carey, MD, for a live recording of the Ophthalmology Times “NeuroOp Guru” during the ...
A grassroots fundraising campaign launched Sept. 30 by Life Care Network is aiming to give a 50-year-old man with a rare neurological disease the care he says he is being denied.
Explore the unique issues of rare disease trials and how “gene silencing” therapies could reshape the future for patients ...
Not a day goes by when Harry Cross doesn't miss his wife. He misses how she gently used to tease him, how she organised his life with quiet efficiency, how she was never lost for the right words to co ...
When the Fillingame family started homesteading, they had no intention of creating a business – but that is what the ...
Limited treatment options and access to care often challenge patients with Friedreich’s ataxia. So, on Sept. 17, the ...
NEW YORK - Lexeo Therapeutics (NASDAQ:LXEO), a $349 million market cap biotech company, announced Tuesday that the FDA is open to pooling data from ongoing Phase I/II studies with pivotal data to ...
The cerebellum is part of the hindbrain that is located below the temporal and occipital lobes of the cerebral cortex. It consists of a thin, densely folded cerebellar cortex surrounding the deep ...
Larimar Therapeutics, Inc. (($LRMR)) announced an update on their ongoing clinical study. Larimar Therapeutics, Inc. is conducting a Phase 1 ...
TipRanks on MSN
Biogen’s Omaveloxolone Study: A Closer Look at Long-Term Safety for Friedreich’s Ataxia
Biogen Inc. (($BIIB)) announced an update on their ongoing clinical study. Biogen Inc. is conducting a study titled An Observational, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback